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Abstract. Human osteopontin (OPN) is a glycosylated phos-
phoprotein which is expressed in a variety of tissues in the body. 
In recent years, accumulating evidence has indicated that the 
aberrant expression of OPN is closely associated with tumouri-
gensis, progression and most prominently with metastasis in 
several tumour types. In this review, we present the current 
knowledge on the expression profiles of OPN and its main splice 
variants in human cancers, as well as the potential implications 
in patient outcome. We also discuss its putative clinical applica-
tion as a cancer biomarker and as a therapeutic target.
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1. Introduction
Osteopontin (OPN) is a bone associated, extracellular matrix 
glycosylated phosphoprotein which is produced by several 
cell types, including osteoblasts, osteoclasts, immune cells, 
endothelial cells, epithelial cells and extra-osseous cells (skin, 
kidney and lung) (1-3). Due to differences in post-translational 
modification (PTM) (phosphorylation, glycosylation, sulfation 
and proteolysis) from different cellular sources, OPN has a 
molecular weight ranging from 41 to 75 kDa, which may have 
a cell type‑specific structure and function (4‑7). OPN plays a 
major role in various normal physiological processes, including 
bone remodelling, immune-regulation, inflammation and 
vascularisation (8,9). In addition, OPN has also been shown 
to be involved in carcinogenesis with multi-functional activi-
ties (10-12).
OPN is involved in a series of biological functions through 
interactions with different integrins and CD44. Therefore, 
OPN is classified as a member of the ʻsmall integrin‑binding 
ligand N-linked glycoproteins’ (SIBLINGs) together with other 
molecules, including bone sialoprotein (BSP), dentin matrix 
protein 1 (DMP1), dentin sialophosphoprotein (DSPP) and 
matrix extracellular phosphoglycoprotein (MEPE) (13). Two 
critical integrin binding sequences of OPN have been identified: 
arginine-glycine-aspartic acid (RGD) and serine-valine-valine-
tyrosine-glutamate-leucine-arginine (SVVYGLR). OPN 
interacts mainly with various αv (particularly αvβ1, αvβ3, αvβ5) 
integrin receptors via the classical RGD sequence, and interacts 
with α9β1, α4β1, α4β7 via SVVYGLR (14-16). In addition, it 
also interacts with the CD44 splice variants, CD44v3, CD44v6 
and CD44v7, via the C-terminal fragment calcium binding 
site (17-20). These properties of OPN induce the activation of 
signal transduction pathways, leading to cell proliferation, adhe-
sion, invasion and migration, which have been demonstrated by 
both in vitro and in vivo models (21-23). The binding of OPN to 
integrins and CD44 initiates a downstream signalling cascade 
via the PI3K/AKT signalling pathway leading to NF-κB medi-
ated cell proliferation and survival (24-26). In additon, through 
the Ras/Raf/MEK/ERK signalling pathway, an OPN-integrin 
complex and subsequent induction of AP-1-dependent gene 
expression, urokinase-type plasminogen activator (uPA) and 
matrix metalloproteinases (MMPs) confer a metastatic pheno-
type on some cancer cell types (27-29). Induced by vascular 
endothelial growth factor (VEGF), OPN and certain integrins 
are able to promote angiogenesis through enhanced endothelial 
cell migration, proliferation and the subsequent formation of 
capillaries, which are all essential requirements for the process 
of angiogenesis (30,31).
2. Expression of OPN in human cancer
OPN has been shown to correlate with tumourigenesis, as well as 
with the progression and metastasis of different malignancies in 
both experimental and clinical studies (Table Ι). The upregulation 
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of OPN expression has been identified in a variety of human 
cancers, including breast, prostate, lung, stomach, pancreatic 
and colorectal cancer, glioma and melanoma (Table Ι).
In these studies, in vitro experiments have also established 
a causal link between OPN expression and cell functions. 
In vitro transfection experiments have demonstrated that 
downregulating OPN gene expression suppressed the progres-
sion of breast cancer cells, which have invasive potential and 
metastatic competence (21). Experimental evidence has further 
suggested that enhanced OPN expression renders a highly 
metastatic phenotype of cancer cells. For example, the enforced 
expression of OPN in non-metastatic rat mammary tumour 
cells has been shown to result in lung metastasis occurring 
in half of the animals that developed primary tumours (23). 
In another study, in glioma cells, elevated levels of OPN and 
VEGF synergistically enhanced the angiogenic properties, via 
integrin αvβ3, on the endothelial cell surface (25). Another 
study demonstrated that the knockdown of OPN in prostate 
cancer cell lines enhanced the cytotoxicity of the chemothera-
peutic drug, daunomycin (DUN), through integrin-mediated 
FAK/P-GP signalling (34). The ectopic expression of OPN in 
DLD1 colon cancer cells has been shown to stimulate EMT 
activation and subsequent migration (41).
In clinical investigations, elevated OPN levels have been 
shown to correlate with increased tumour burden (stage, grade 
and tumour size), a poor prognosis and reduced survival, although 
discrepancies remain. For example, the increased expression 
of OPN in plasma and tumour tissues has been identified in 
breast cancer patients and has been shown to be associated with 
metastatic disease and decreased survival (35). Similarly, in 
advanced gastric cancer, patients with OPN-positive cancer (as 
determined by immunohistochemistry) have a decrease in their 
5-year survival, when compared with those with OPN-negative 
cancer (40). In colorectal cancer (CRC) patients, increased OPN 
mRNA levels have been shown to significantly correlate with 
stage, lymph node metastasis and lymphatic or venous inva-
sion, as well as with lower disease-free and overall survival 
rates (41,42). A study on patients with pancreatic ductal adeno-
carcinoma (PDAC) demonstrated that serum levels of OPN 
are elevated with advanced tumour grades (44). Elevated OPN 
levels have also been strongly associated with increased stage, 
grade and tumour size in melanoma patients (52). In early stage 
non-small cell lung cancer (NSCLC) patients high OPN plasma 
levels were observed which were reduced after surgical tumour 
resection. However, in those patients which showed recurrence 
after surgery OPN plasma levels re-elevated, indicating that 
OPN is not only a potential diagnostic marker in NSCLC, but 
also has potential as a tool for detecting tumour recurrence after 
treatment (53). Thus, OPN may be a useful biomarker to monitor 
cancer progression and a significant predictor of poor prognosis 
and survival rates.
3. Expression of OPN splice variants in human cancers
The alternative splice-generation of multiple mRNA products 
from a single gene is a critical mechanism for generating 
proteomic diversity. The OPN precusor-mRNA (pre-mRNA) 
is subject to alternative splicing, which generates three splice 
variants, OPN-a (consists of all exons), OPN-b (which lacks 
exon 5) and OPN-c (which lacks exon 4) (Fig. 1).
Recent studies have demonstrated that the expression of 
OPN splice variants in malignancies is cell‑type/tissue specific 
and may have functional heterogeneity (Table II). For example, 
Pang et al reported that OPN-c is selectively expressed in 
breast cancer tissue (57). In their study on 170 breast cancer 
patients, OPN-c protein staining was positive in 70% of all 
of the samples and was significantly higher in tumour tissues 
compared to normal tissues. The study indicated an inverse 
correlation between OPN-c and E-cadherin, an established 
tumour suppressor. However, the observations by the same 
authors that OPN-c also inversely correlated with β-catenin and 
that E-cadherin positively correlated β-catenin are intriguing. 
Despite β-catenin working with E-cadherin to form cell-cell 
adhesion complexes, β-catenin has been classically regarded as 
an oncogenic protein. Thus, the true link between OPN-c and 
the cell adhesion complex requires further study and one has to 
delineate the cellular location of β-catenin (namely membrane-
associated, cytoplasmic and nucleus) in this context. However, 
the study by Pang has clearly demonstrated that high levels of 
OPN-c staining in breast tumours are associated with TNM 
staging, nodal involvement, recurrence and metastasis, and 
interestingly with the triple negativity of the tumours and, thus 
is an independent prognostic indicator for these patients (57). 
Another study by Sun et al demonstrated that each of the three 
OPN splice variants was able to increase the growth of breast 
tumours, in vivo (56). It is noteworthy that OPN-a appears more 
effective in promoting tumour growth than the other two splice 
forms.
Conflicting evidence also exists regarding the function 
of OPN isoforms in hepatocellular carcinoma (HCC). It has 
been previously demonstrated that tumour tissue predomi-
nantly expressed OPN-a and OPN-b, and the ratio of OPN-a 
and OPN-b to OPN-c increased substantially as the tumours 
progressed in SK-Hep1 cells and Hep3B cells (67). Thus, it is 
possible that OPN-a and OPN-b may be associated with a poor 
prognosis, and OPN-c may prevent both cell migration and 
invasion in more migratory and invasive cells. By contrast, in 
another study, Takafuji et al (68) reported that the increased 
expression of OPN-c in Hep3B cells appeared to enhance 
cellular invasion and metastatic potential due to the formation 
of OPN-c fragment by MMP-9.
A number of studies have also explored OPN splice vari-
ants in lung cancer. Sun et al (59) found that, compared with 
normal lung tissue, the majority of NSCLC samples predomi-
nantly expressed OPN-a. A similar observation was made by 
Blasberg et al (61), who reported that OPN-a was the dominant 
isoform, whereas little OPN-b and no OPN-c expression was 
detected in lung cancer cell lines that endogenously expressed 
OPN (A549, H460, H157, H1299 and Calu-3). Functionally, 
OPN-a promotes angiogenesis in lung cancer by stimulating 
endothelial cells, likely by binding to the αvβ3 integrin and 
increasing VEGF expression and secretion. In their study, 
OPN-b appeared to increase tubule formation merely by 
activating endothelial cells, and did so without a concomi-
tant enhancement of VEGF secretion or expression. OPN-c 
had a predominantly negative effect significantly inhibiting 
angiogenesis and VEGF secretion. However, Zhao et al (60) 
suggested that OPN-b strongly affected cell proliferation, 
while OPN-c was closely related to the invasive behaviour of 
the NSCLC cell line, A549.
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These studies emphasise that OPN splice variants may 
have diverse expression patterns and different functional roles, 
which may be cancer type‑specific.
4. Polymorphism of OPN and OPN splice variants in cancers
Secreted OPN (sOPN) and intracellular OPN (iOPN). OPN 
has mainly been studied as a secreted protein, but recent 
studies have shown that, in some cases, OPN is not secreted 
and instead will be found in the cytoplasm and nucleus. Mouse 
OPN mRNA has the canonical AUG translation initiation site 
and an alternative translation initiation site. When transla-
tion initiates from the canonical site, the peptide produced 
is targeted to secretory vesicles. On the other hand, when 
translation starts from the alternative translation initiation site, 
the peptide produced is accompanied by deletion of a signal 
sequence and localises in the cytoplasm (76,77). Although 
sOPN and iOPN are generated from the same OPN mRNA 
species, the biological outcomes mediated by the two isoforms 
may differ (78). The role of human sOPN in cell physiology 
has been extensively studied in different cellular contexts. 
Compared with sOPN, the biological roles of iOPN have only 
begun to emerge over the past several years. Thus far, iOPN 
has been found in calvarial cells, dendritic cells, macrophages 
and nerve cells (77,79,80). It is involved in cell motility, cyto-
skeletal rearrangement and mitosis by physical association with 
polo-like kinase-1 (Plk-1) (81-83). Similarly, these two isoforms 
may play distinct roles in cancer progression. Indeed, in 
patients with various solid tumours, sOPN has been proposed 
as a diagnostic marker to distinguish either resectable cases or 
predict survival rates (43,84,85). However, cytoplasmic OPN 
expression has appeared not to correlate with average tumour 
size, tumour stage and nodal status (10,86). The same has been 
observed for OPN splice variants. For example, in a study on 
expression patterns of OPN variants and its functions on cell 
apoptosis and invasion in glioma cells, Yan et al presumed that 
the secretary nature of OPN splice variants may be induced 
by the absence of exon 5 or exon 4. As a consequence, OPN-b 
without out exon 5 may aggregate within the cytoplasm and 
exert a significant anti‑apoptotic effect, while OPN‑c without 
exon 4 may be easily secreted to culture supernatants and has a 
remarkable effect on cellular invasion (74).
Therefore, it would be necessary to delineate which isoform 
of OPN is responsible for pathophysiological events, and 
furthermore, sOPN and iOPN should be independently targeted 
in any potential therapies.
Host-derived OPN and tumour-derived OPN. Tumour cells and 
their microenvironment mutually influence tumour formation, 
progression and metastasis. The tumour microenvironment 
includes a variety of non‑tumour cell types, such as fibroblasts, 
immune cells, vascular and smooth muscle cells. The host's 
reaction to neoplastic cells and the ability of environmental 
modification by tumour cells themselves are both involved in 
Figure 1. Structural features of the three osteopontin (OPN) splice variants. OPN-a is the full-length isoform with 6 translated exons (314 aa), OPN-b lacks 
exon 5 (300 aa), and OPN‑c lacks exon 4 (287 aa). All OPN variants possess functional domains: arginine‑glycine‑aspartic acid (RGD) domain (159‑161), 
serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR) domain (162-168), thrombin cleavage site, calcium binding domain (216-228) and 
heparin binding domain. Integrin binding occurs at RGD and SVVYGLR sequences, whilst the CD44 variant receptor binding occurs near the C-terminus. 
Phosphorylation sites are throughout the whole precusor-mRNA (pre-mRNA). Thrombin cleavage and matrix metalloproteinase (MMP) cleavage sites are 
present in all three splice variants. Compared with the full-length isoform (OPN-a), OPN-b misses certain phosphorylation sites, while OPN-c is unable to 
undergo transglutaminase cross-linking. To some extent, the structural differences that exist between the three OPN isoforms may contribute to their clinical 
and functional differences.
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tumour formation. A number of studies have demonstrated that 
OPN can be synthesised by tumour and other cells types in the 
tumour microenvironment, such as macrophages and stromal 
cells (87,88). However, whether tumour-derived OPN differs 
from host-derived OPN, either structurally or functionally, is 
largely unknown. There is evidence indicating that the role of 
OPN in metastasis is dependent on the site of production. For 
example, historically, stroma-derived OPN has been considered 
to be intrinsically involved in the defensive mechanism against 
tumour development by acting as a macrophage chemoat-
tractant, yet stroma-derived OPN can effectively regulate 
melanoma growth, angiogenesis and metastasis with the host 
OPN-tumour interaction (89-91). In addition, tumour-derived 
OPN may promote the metastatic process by inhibiting macro-
phage cytotoxicity against tumours (92). By contrast, some 
evidence suggests that at least in some instances, the presence 
of OPN in macrophages promote the development and activity 
of type I natural killer (NK) T cells (NK T cells) and that OPN 
may inhibit tumour activity via these NK cells (93).
Thus, host-derived OPN and tumour-derived OPN may 
mutually affect each other and the interaction between the 
tumour and tumour microenvironment may determine whether 
the overall effect of OPN will be tumour promoting or tumour 
inhibiting.
OPN splice variants polymorphism in cancers. The similar 
heterogeneity of OPN splice variants exists in cancers. the 
differential effects of the three splice variants may be due to 
the distinctive functions of the spliced exons that individual 
OPN isoforms contain. For example, the sequences encoded by 
exon 5, absent in OPN-b, contain one of several clusters of phos-
phorylated serine/threonine residues. Exon 4 however encodes 
two glutamine residues essential for transglutaminase cross-
linking. As exon 4 is absent in OPN-c, but present in OPN-a and 
OPN‑b, OPN‑c has no specific functions exerted by exon 4 (94). 
In breast cancer cells, it has been reported that OPN-a, not 
OPN-c may have a tendency to aggregate in response to physical 
concentrations of calcium, and thus have a greater capacity to 
enhance cell adhesion (95). By contrast, OPN-c may be more 
soluble and able to support anchorage-independent growth of 
breast cancer cells (96,97). OPN-c possesses a more exposed 
Arg-Ser-Lys (RSK) motif compared to OPN-a (98). Using the 
RSK motif as a cleavage site, systemically circulating thrombin 
can cleave OPN-c easily into two fragments, the N-terminal 
and C-terminal, of approximately equivalent size (98). The 
N-terminal GRGDS-containing fragment produced by thrombin 
cleavage has the potential to enhance tumour cell migra-
tion (98). The thrombin-cleaved C-terminal fragment of OPN 
has also been reported to influence breast cancer cell migration 
and invasion in vitro (99). The absence of the transglutaminase 
acting site in OPN-c may explain why OPN-c cannot be cross-
linked with the extracellular matrix (94).
On the other hand, some investigations suggest that the 
possible reasons for OPN isoforms cell‑type specific patterns 
and their roles are closely related to these differing PTMs of 
the three OPN splice variants. Gimba et al demonstrated that 
the potential of OPN‑a, OPN‑b and OPN‑c for specific phos-
phorylation patterns, and the deletion of exon 4 or 5 altered the 
pattern of PTMs, ultimately resulting in functional modifica-
tions (46).
5. Conclusion and future perspectives
OPN was initially identified in bone and later characterised 
based on its splice variants and their structures and func-
tions. It is now well established that the isoforms of OPN are 
differentially expressed in many tumour types and play critical 
roles at different stages of cancer development and progression. 
OPN may be a useful biomarker to monitor cancer progres-
sion and one of the significant predictors of poor prognosis and 
survival rates, in certain cancers for example in breast cancer 
and lung cancer. Thus, OPN may have several potential clinical 
implications: firstly, as a convenient tool for clinical test. As 
a secreted protein, OPN can easily detected in body fluids, 
such as blood, urine and body cavity fluids (namely pleural 
and peritoneal ascites). This gives rise to convenient sampling, 
taking advantages of sample quantity, safe detection, proce-
dure speed and minimal invasiveness, collectively providing 
a convenient approach for clinical testing. Secondly, the power 
of combining OPN with other traditional biomarkers, such 
as VEGF, MMPs and E-cadherin, for example, provide more 
accurate predictions for prognosis and potential response to 
therapies (43,50,100).
Yet, changes remain, especially given the complexity of 
the distribution patterns and presence of the variant forms for 
OPN. Methods of OPN detection are currently very limited. 
Traditional protein detection methods such as ELISA have 
shown their limit due to a lack of sensitivity and the nature 
of samples required for the testings. Several studies have 
focused on the cost-effectiveness and ease of implementing 
immunosensors for OPN detection demonstrating better sensi-
tivity than ELISA assays, and providing greater potential to 
develop simple test kits for OPN combined with other protein 
biomarkers (101-104).
Due to the pre- and post-translational regulation, the expres-
sion and function patterns of OPN isoforms usually exhibit 
tissue specificity. It has been suggested that this provides the 
possibility to develop cancer therapy strategies to target those 
OPN isoforms which are specific to tumour cells or play a key 
role in tumour progression. But the pre- and post-translational 
regulation are complex and ubiquitous, developing drugs that 
target only cancer cells with minimal impact on healthy cells is 
extremely difficult. Thus the expression patterns and activities 
of tumour‑specific OPN isoforms should be further defined 
with multidisciplinary and large scale clinical study. The 
development of specific OPN‑based approaches for individual 
cancer types is equally important as well.
Collectively, OPN and its variants have been shown to 
play an important role in regulating the aggressive nature of 
cancer cells and promote the growth of tumours. Although 
there is more to learn with regards to the mechanisms of action 
of the specific OPN variants, it is clear that there is clinical 
prospect(s) for this protein and its variants. OPN appears to 
have good clinical value in evaluating disease progression and 
cancer patient outcome. There is a good prospect for devel-
oping a OPN based clinical test for cancer patients in order 
to evaluate their prognosis and response to therapies. Wht is 
most exciting is the prospect of developing tools to target the 
protein and its variants in novel ways. It is anticipated that in 
the coming years we will see some significant progress along 
these fronts.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 9
Acknowledgements
The authors wish to thank Cancer Research Wales, Cardiff 
University China Medical Scholarship, Life Science Research 
Network for Wales (LSRNW) and the Albert Hung Foundation 
for supporting their study.
References
 1. Giachelli CM, Liaw L, Murry CE, Schwartz SM and Almeida M: 
Osteopontin expression in cardiovascular diseases. Ann NY 
Acad Sci 760: 109‑126, 1995.
 2. Weber GF and Cantor H: The immunology of Eta‑1/osteopontin. 
Cytokine Growth Factor Rev 7: 241‑248, 1996.
 3. Denhardt DT and Noda M: Osteopontin expression and function: 
role in bone remodeling. J Cell Biochem Suppl 30‑31 (S30‑31): 
92-102, 1998.
 4. Sodek J, Ganss B and McKee MD: Osteopontin. Crit Rev Oral 
Biol Med 11: 279‑303, 2000.
 5. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, 
Denhardt DT and Sørensen ES: Cell type‑specific post‑transla-
tional modifications of mouse osteopontin are associated with 
different adhesive properties. J Biol Chem 282: 19463‑19472, 
2007.
 6. Christensen B, Nielsen MS, Haselmann KF, Petersen TE and 
Sørensen ES: Post‑translationally modified residues of native 
human osteopontin are located in clusters: identification of 
36 phosphorylation and five O-glycosylation sites and their 
biological implications. Biochem J 390: 285‑292, 2005.
 7. Christensen B, Petersen TE and Sørensen ES: Post‑translational 
modification and proteolytic processing of urinary osteopontin. 
Biochem J 411: 53‑61, 2008.
 8. Denhardt DT and Guo X: Osteopontin: a protein with diverse 
functions. FASEB J 7: 1475‑1482, 1993.
 9. Cho HJ, Cho HJ and Kim HS: Osteopontin: a multifunctional 
protein at the crossroads of inflammation, atherosclerosis, and 
vascular calcification. Curr Atheroscler Rep 11: 206‑213, 2009.
10. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, 
Chambers AF and Yeatman TJ: Correlation of osteopontin 
protein expression and pathological stage across a wide variety 
of tumor histologies. Clin Cancer Res 10: 184‑190, 2004.
11. Rittling SR and Chambers AF: Role of osteopontin in tumour 
progression. Br J Cancer 90: 1877‑1881, 2004.
12. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M and 
Rudland PS: The regulation and role of osteopontin in malignant 
transformation and cancer. Cytokine Growth Factor Rev 17: 
463-474, 2006.
13. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW and 
Fedarko NS: Small integrin‑binding ligand N‑linked glyco-
proteins (SIBLINGs): multifunctional proteins in cancer. Nat 
Rev Cancer 8: 212‑226, 2008.
14. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R 
and Giachelli CM: Osteopontin N‑terminal domain contains a 
cryptic adhesive sequence recognized by alpha9beta1 integrin. J 
Biol Chem 271: 28485‑28491, 1996.
15. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, 
Higashiyama S, Saitoh Y, Yamakido M, Taooka Y and 
Sheppard D: The integrin alpha(9)beta(1) binds to a novel 
recognition sequence (SVVYGLR) in the thrombin-cleaved 
amino‑terminal fragment of osteopontin. J Biol Chem 274: 
36328-36334, 1999.
16. Scatena M, Liaw L and Giachelli CM: Osteopontin: a multifunc-
tional molecule regulating chronic inflammation and vascular 
disease. Arterioscler Thromb Vasc Biol 27: 2302‑2309, 2007.
17. Sun BS, Li Y, Zhang ZF, You J and Wang CL: Osteopontin 
combined with CD44v6, a novel prognostic biomarker in 
non-small cell lung cancer undergoing curative resection. Ann 
Thorac Surg 96: 1943‑1951, 2013.
18. Gao YL, Xing LQ, Ren TJ, Hou JF, Xue Q, Liu C and Han YM: 
The expression of osteopontin in breast cancer tissue and its rela-
tionship with p21ras and CD44V6 expression. Eur J Gynaecol 
Oncol 37: 41‑47, 2016.
19. Yang L, Shang X, Zhao X, Lin Y and Liu J: Correlation study 
between OPN, CD44v6, MMP-9 and distant metastasis in 
laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou 
Tou Jing Wai Ke Za Zhi 26: 989‑992, 2012 (In Chinese).
20. Kim JS, Bashir MM and Werth VP: Gottron's papules exhibit 
dermal accumulation of CD44 variant 7 (CD44v7) and its 
binding partner osteopontin: a unique molecular signature. J 
Invest Dermatol 132: 1825‑1832, 2012.
21. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, 
Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, et al: 
Role of the integrin-binding protein osteopontin in lymphatic 
metastasis of breast cancer. Am J Pathol 169: 233‑246, 2006.
22. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, 
Vice C, Brustugun OT, Denko NC, et al: The RGD domain of 
human osteopontin promotes tumor growth and metastasis 
through activation of survival pathways. PLoS One 5: e9633, 
2010.
23. Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, 
Ohe Y, Tominaga S, Takagi Y, Sasaki S, et al: Abrogation of 
the interaction between osteopontin and alphavbeta3 integrin 
reduces tumor growth of human lung cancer cells in mice. Lung 
Cancer 57: 302‑310, 2007.
24. Wu CM, Chen PC, Li TM, Fong YC and Tang CH: Si‑Wu‑tang 
extract stimulates bone formation through PI3K/Akt/NF-κB 
signaling pathways in osteoblasts. BMC Complement Altern 
Med 13: 277, 2013.
25. Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, 
Pu P, et al: Overexpression of osteopontin induces angiogenesis 
of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO 
signaling pathway in glioma cells. Eur J Cell Biol 90: 642‑648, 
2011.
26. Ogata T, Ueyama T, Nomura T, Asada S, Tagawa M, Nakamura T, 
Takahashi T, Matsubara H and Oh H: Osteopontin is a 
myosphere-derived secretory molecule that promotes angiogenic 
progenitor cell proliferation through the phosphoinositide 3-kinase/
Akt pathway. Biochem Biophys Res Commun 359: 341‑347, 
2007.
27. Chen RX, Xia YH, Xue TC, Zhang H and Ye SL: Down‑regulation 
of osteopontin inhibits metastasis of hepatocellular carcinoma 
cells via a mechanism involving MMP‑2 and uPA. Oncol Rep 25: 
803-808, 2011.
28. Mi Z, Guo H, Wai PY, Gao C and Kuo PC: Integrin‑linked kinase 
regulates osteopontin-dependent MMP-2 and uPA expression to 
convey metastatic function in murine mammary epithelial cancer 
cells. Carcinogenesis 27: 1134‑1145, 2006.
29. Tuck AB, Hota C and Chambers AF: Osteopontin(OPN)‑induced 
increase in human mammary epithelial cell invasiveness 
is urokinase (uPA)‑dependent. Breast Cancer Res Treat 70: 
197-204, 2001.
30. Kerenidi T, Kazakou AP, Lada M, Tsilioni I, Daniil Z and 
Gourgoulianis KI: Clinical significance of circulating osteo-
pontin levels in patients with lung cancer and correlation with 
VEGF and MMP‑9. Cancer Invest 34: 385‑392, 2016.
31. Babarović E, Valković T, Budisavljević I, Balen I, Štifter S, 
Duletić‑Načinović A, Lučin K and Jonjić N: The expression of 
osteopontin and vascular endothelial growth factor in correlation 
with angiogenesis in monoclonal gammopathy of undetermined 
significance and multiple myeloma. Pathol Res Pract 212: 
509-516, 2016.
32. Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B and 
Gu X: Clinical and prognostic significance of OPN and VEGF 
expression in patients with non-small-cell lung cancer. Cancer 
Epidemiol 39: 539‑544, 2015.
33. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, 
Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A and 
Syrigos KN: The clinical significance of serum markers of bone 
turnover in NSCLC patients: surveillance, management and 
prognostic implications. Anticancer Res 29: 1651‑1657, 2009.
34. Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS and 
Fu WM: Upregulation of drug transporter expression by osteo-
pontin in prostate cancer cells. Mol Pharmacol 83: 968‑977, 
2013.
35. Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW and 
Brackstone M: Role of plasma osteopontin as a biomarker in 
locally advanced breast cancer. Am J Transl Res 7: 723‑732, 
2015.
36. Friedmann-Morvinski D, Bhargava V, Gupta S, Verma IM 
and Subramaniam S: Identification of therapeutic targets for 
glioblastoma by network analysis. Oncogene 35: 608‑620, 2016.
37. Güttler A, Giebler M, Cuno P, Wichmann H, Keßler J, Ostheimer C, 
Söling A, Strauss C, Illert J, Kappler M, et al: Osteopontin and 
splice variant expression level in human malignant glioma: 
radiobiologic effects and prognosis after radiotherapy. Radiother 
Oncol 108: 535‑540, 2013.
HAO et al:  OSTEOPONTIN IN CANCER10
38. Etiz D, Ataizi FC, Bayman E, Akcay M, Acikalin MF, Colak E 
and Ciftci E: Prognostic value of osteopontin in patients treated 
with primary radiotherapy for head and neck cancer. Asian Pac J 
Cancer Prev 14: 5175‑5178, 2013.
39. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, Peng YF, 
Shinkai M, Akai F, Yasuda T, et al: Immunohistochemical 
expression of osteopontin in gastric cancer. J Gastrointest 
Surg 13: 1577‑1582, 2009.
40. Higashiyama M, Ito T, Tanaka E and Shimada Y: Prognostic 
significance of osteopontin expression in human gastric 
carcinoma. Ann Surg Oncol 14: 3419‑3427, 2007.
41. Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li HS, 
Cheng NS, Pak RC, Cheung AH, et al: Post‑operative plasma 
osteopontin predicts distant metastasis in human colorectal 
cancer. PLoS One 10: e0126219, 2015.
42. Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, 
Foo CC, Poon JT, et al: Osteopontin overexpression induced 
tumor progression and chemoresistance to oxaliplatin through 
induction of stem-like properties in human colorectal cancer. 
Stem Cells Int 2015: 247892, 2015.
43. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, 
Boucher KM and Mulvihill SJ: Serum osteopontin and tissue 
inhibitor of metalloproteinase 1 as diagnostic and prognostic 
biomarkers for pancreatic adenocarcinoma. Pancreas 42: 
193-197, 2013.
44. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, 
Rahman A, Hruban RH, Yeo CJ and Goggins M: Evaluation of 
osteopontin as biomarker for pancreatic adenocarcinoma. Cancer 
Epidemiol Biomarkers Prev 13: 487‑491, 2004.
45. Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, 
Wang H, Yang Y, et al: Osteopontin induces autophagy to 
promote chemo-resistance in human hepatocellular carcinoma 
cells. Cancer Lett 383: 171‑182, 2016.
46. Gimba ER and Tilli TM: Human osteopontin splicing isoforms: 
known roles, potential clinical applications and activated 
signaling pathways. Cancer Lett 331: 11‑17, 2013.
47. Salem M, Atti SA, Raziky ME, Darweesh SK and Sharkawy ME: 
Clinical significance of plasma osteopontin level as a biomarker of 
hepatocellular carcinoma. Gastroenterology Res 6: 191‑199, 2013.
48. Xu ST, Guo C, Ding X, Fan WJ, Zhang FH, Xu WL and Ma YC: 
Role of osteopontin in the regulation of human bladder cancer 
proliferation and migration in T24 cells. Mol Med Rep 11: 
3701-3707, 2015.
49. Moszynski R, Szubert S, Szpurek D, Michalak S and Sajdak S: 
Role of osteopontin in differential diagnosis of ovarian tumors. J 
Obstet Gynaecol Res 39: 1518‑1525, 2013.
50. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, 
Yoshinaga M and Douchi T: Preoperative plasma osteopontin 
level as a biomarker complementary to carbohydrate antigen 125 
in predicting ovarian cancer. J Obstet Gynaecol Res 32: 309‑314, 
2006.
51. Subramani VN, Narasimhan M, Thiyagarajan M, Munuswamy BD 
and Jayamani L: Expression of osteopontin in oral squamous cell 
carcinoma and its surgical margins-an immunohistochemical 
study. J Clin Diagn Res 9: ZC66‑ZC69, 2015.
52. Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovács N, 
Adany R and Balazs M: The role of osteopontin expression in 
melanoma progression. Tumour Biol 36: 7841‑7847, 2015.
53. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and 
Donington JS: Reduction of elevated plasma osteopontin levels 
with resection of non‑small‑cell lung cancer. J Clin Oncol 28: 
936-941, 2010.
54. Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, 
Blomqvist C, Fjällskog ML and Weber GF: Nuclear osteopontin‑c 
is a prognostic breast cancer marker. Br J Cancer 112: 729‑738, 
2015.
55. Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, 
Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E and 
Peiró G: Association of increased osteopontin and splice variant‑c 
mRNA expression with HER2 and triple-negative/basal-like 
breast carcinomas subtypes and recurrence. Hum Pathol 45: 
504-512, 2014.
56. Sun J, Feng A, Chen S, Zhang Y, Xie Q, Yang M, Shao Q, Liu J, 
Yang Q, Kong B, et al: Osteopontin splice variants expressed 
by breast tumors regulate monocyte activation via MCP-1 and 
TGF-β1. Cell Mol Immunol 10: 176‑182, 2013.
57. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, 
Yan S, Dong X, et al: Prognostic values of osteopontin‑c, 
E-cadherin and β‑catenin in breast cancer. Cancer Epidemiol 37: 
985-992, 2013.
58. Patani N, Jouhra F, Jiang W and Mokbel K: Osteopontin 
expression profiles predict pathological and clinical outcome in 
breast cancer. Anticancer Res 28: 4105‑4110, 2008.
59. Sun SJ, Wu CC, Sheu GT, Chang HY, Chen MY, Lin YY, 
Chuang CY, Hsu SL and Chang JT: Integrin β3 and CD44 levels 
determine the effects of the OPN-a splicing variant on lung 
cancer cell growth. Oncotarget 7: 55572‑55584, 2016.
60. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y and Li W: 
Osteopontin as a potential biomarker of proliferation and inva-
siveness for lung cancer. J Cancer Res Clin Oncol 137: 1061‑1070, 
2011.
61. Blasberg JD, Goparaju CM, Pass HI and Donington JS: Lung 
cancer osteopontin isoforms exhibit angiogenic functional 
heterogeneity. J Thorac Cardiovasc Surg 139: 1587‑1593, 2010.
62. Nakamura KD, Tilli TM, Wanderley JL, Palumbo A Jr, 
Mattos RM, Ferreira AC, Klumb CE4, Nasciutti LE and 
Gimba ER: Osteopontin splice variants expression is involved 
on docetaxel resistance in PC3 prostate cancer cells. Tumour 
Biol 37: 2655‑2663, 2016.
63. Tilli TM, Bellahcène A, Castronovo V and Gimba ER: Changes 
in the transcriptional profile in response to overexpression 
of the osteopontin-c splice isoform in ovarian (OvCar-3) and 
prostate (PC‑3) cancer cell lines. BMC Cancer 14: 433, 2014.
64. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, 
Faria PA, Bellahcène A, Castronovo V and Gimba ER: Both 
osteopontin-c and osteopontin-b splicing isoforms exert 
pro‑tumorigenic roles in prostate cancer cells. Prostate 72: 
1688-1699, 2012.
65. Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, 
Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, et al: 
Osteopontin (OPN/SPP1) isoforms collectively enhance tumor 
cell invasion and dissemination in esophageal adenocarcinoma. 
Oncotarget 6: 22239‑22257, 2015.
66. Zhang MX, Xu YJ, Zhu MC and Yan F: Overexpressed 
ostepontin-c as a potential biomarker for esophageal squamous 
cell carcinoma. Asian Pac J Cancer Prev 14: 7315‑7319, 2013.
67. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, 
Yeom YI and Kim KW: Osteopontin splice variants differentially 
modulate the migratory activity of hepatocellular carcinoma cell 
lines. Int J Oncol 35: 1409‑1416, 2009.
68. Takafuji V, Forgues M, Unsworth E, Goldsmith P and Wang XW: 
An osteopontin fragment is essential for tumor cell invasion in 
hepatocellular carcinoma. Oncogene 26: 6361‑6371, 2007.
69. Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu B and Zhu Z: 
Osteopontin splice variants differentially exert clinicopatho-
logical features and biological functions in gastric cancer. Int J 
Biol Sci 9: 55‑66, 2013.
70. Siddiqui AA, Jones E, Andrade D, Shah A, Kowalski TE, 
Loren DE, Chipitsyna G and Arafat HA: Osteopontin splice 
variant as a potential marker for metastatic disease in pancreatic 
adenocarcinoma. J Gastroenterol Hepatol 29: 1321‑1327, 2014.
71. Sarosiek K, Jones E, Chipitsyna G, Al-Zoubi M, Kang C, 
Saxena S, Gandhi AV, Sendiky J, Yeo CJ and Arafat HA: 
Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what 
is one got to do with the other? A new role for OPN. J Gastrointest 
Surg 19: 639‑650, 2015.
72. Ferreira LB, Eloy C, Pestana A, Lyra J, Moura M, Prazeres H, 
Tavares C, Sobrinho‑Simões M, Gimba E and Soares P: 
Osteopontin expression is correlated with differentiation 
and good prognosis in medullary thyroid carcinoma. Eur J 
Endocrinol 174: 551‑561, 2016.
73. Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, 
Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, et al: 
Osteopontin-a splice variant is overexpressed in papillary thyroid 
carcinoma and modulates invasive behavior. Oncotarget 7: 
52003-52016, 2016.
74. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, 
Kang C, Pu P, et al: Expression pattern of osteopontin splice 
variants and its functions on cell apoptosis and invasion in 
glioma cells. Neuro‑oncol 12: 765‑775, 2010.
75. Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, 
Kotzsch M, Taubert H, Vordermark D and Bache M: Prognostic 
impact of mRNA levels of osteopontin splice variants in soft 
tissue sarcoma patients. BMC Cancer 12: 131, 2012.
76. Inoue M and Shinohara ML: Intracellular osteopontin (iOPN) 
and immunity. Immunol Res 49: 160‑172, 2011.
77. Shinohara ML, Kim HJ, Kim JH, Garcia VA and Cantor H: 
Alternative translation of osteopontin generates intracellular and 
secreted isoforms that mediate distinct biological activities in 
dendritic cells. Proc Natl Acad Sci USA 105: 7235‑7239, 2008.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11
78. Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, 
Kim BY, Radisky DC, Storz P, Copland JA and Tun HW: 
Osteopontin is a multi-faceted pro-tumorigenic driver for central 
nervous system lymphoma. Oncotarget 7: 32156‑32171, 2016.
79. Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C and Sodek J: 
Single cell analysis of intracellular osteopontin in osteogenic 
cultures of fetal rat calvarial cells. J Cell Physiol 170: 88‑100, 
1997.
80. Zhao W, Wang L, Zhang L, Yuan C, Kuo PC and Gao C: 
Differential expression of intracellular and secreted osteopontin 
isoforms by murine macrophages in response to toll-like receptor 
agonists. J Biol Chem 285: 20452‑20461, 2010.
81. Junaid A, Moon MC, Harding GE and Zahradka P: Osteopontin 
localizes to the nucleus of 293 cells and associates with polo-like 
kinase‑1. Am J Physiol Cell Physiol 292: C919‑C926, 2007.
82. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, 
McCulloch CA and Sodek J: Intracellular osteopontin is an 
integral component of the CD44-ERM complex involved in cell 
migration. J Cell Physiol 184: 118‑130, 2000.
83. Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, 
Glimcher LH and Cantor H: Osteopontin expression is essential 
for interferon-alpha production by plasmacytoid dendritic cells. 
Nat Immunol 7: 498‑506, 2006.
84. Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, May D, 
Anton‑Culver H, Ziogas A, Bronner MP and Brentnall TA: Pilot 
study of blood biomarker candidates for detection of pancreatic 
cancer. Pancreas 39: 981‑988, 2010.
85. Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: 
Elevated serum bone sialoprotein and osteopontin in colon, 
breast, prostate, and lung cancer. Clin Cancer Res 7: 4060‑4066, 
2001.
86. Collins AL, Rock J, Malhotra L, Frankel WL and Bloomston M: 
Osteopontin expression is associated with improved survival in 
patients with pancreatic adenocarcinoma. Ann Surg Oncol 19: 
2673-2678, 2012.
87. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, 
Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ 
and Cantor H: Eta‑1 (osteopontin): an early component of type‑1 
(cell‑mediated) immunity. Science 287: 860‑864, 2000.
88. Chan SC, Tekari A, Benneker LM, Heini PF and Gantenbein B: 
Osteogenic differentiation of bone marrow stromal cells is 
hindered by the presence of intervertebral disc cells. Arthritis 
Res Ther 18: 29, 2015.
89. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M and 
Kundu GC: Functional characterization of stromal osteopontin 
in melanoma progression and metastasis. PLoS One 8: e69116, 
2013.
90. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, 
Chen CH and Yang PC: Tumor‑associated macrophages: the 
double‑edged sword in cancer progression. J Clin Oncol 23: 
953-964, 2005.
91. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, 
Wu WZ, Wang L, Tang ZY and Sun HC: High expression of 
macrophage colony-stimulating factor in peritumoral liver 
tissue is associated with poor survival after curative resection 
of hepatocellular carcinoma. J Clin Oncol 26: 2707‑2716, 2008.
 92. Wai PY, Guo L, Gao C, Mi Z, Guo H and Kuo PC: Osteopontin 
inhibits macrophage nitric oxide synthesis to enhance tumor 
proliferation. Surgery 140: 132‑140, 2006.
 93. Sato K, Iwai A, Nakayama Y, Morimoto J, Takada A, 
Maruyama M, Kida H, Uede T and Miyazaki T: Osteopontin 
is critical to determine symptom severity of influenza through 
the regulation of NK cell population. Biochem Biophys Res 
Commun 417: 274‑279, 2012.
 94. Collighan RJ and Griffin M: Transglutaminase 2 cross‑linking 
of matrix proteins: biological significance and medical appli-
cations. Amino Acids 36: 659‑670, 2009.
 95. He B, Mirza M and Weber GF: An osteopontin splice variant 
induces anchorage independence in human breast cancer cells. 
Oncogene 25: 2192‑2202, 2006.
 96. Shen H and Weber GF: The osteopontin‑c splice junction is 
important for anchorage‑independent growth. Mol Carcinog 53: 
480-487, 2014.
 97. Shi Z, Wang B, Chihanga T, Kennedy MA and Weber GF: 
Energy metabolism during anchorage-independence. Induction 
by osteopontin‑c. PLoS One 9: e105675, 2014.
 98. Sivakumar S and Niranjali Devaraj S: Tertiary structure 
prediction and identification of druggable pocket in the cancer 
biomarker ‑ osteopontin‑c. J Diabetes Metab Disord 13: 13, 2014.
 99. Mi Z, Oliver T, Guo H, Gao C and Kuo PC: Thrombin‑cleaved 
COOH(-) terminal osteopontin peptide binds with cyclophilin C 
to CD147 in murine breast cancer cells. Cancer Res 67: 
4088-4097, 2007.
100. Chimparlee N, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, 
Payungporn S, Poovorawan Y and Tangkijvanich P: Diagnostic 
and prognostic roles of serum osteopontin and osteopontin 
promoter polymorphisms in hepatitis B-related hepatocellular 
carcinoma. Asian Pac J Cancer Prev 16: 7211‑7217, 2015.
101. Sharma A, Hong S, Singh R and Jang J: Single‑walled carbon 
nanotube based transparent immunosensor for detection of a 
prostate cancer biomarker osteopontin. Anal Chim Acta 869: 
68-73, 2015.
102. Faria M, Halquist MS, Yuan M, Mylott W Jr, Jenkins RG and 
Karnes HT: Comparison of a stable isotope labeled (SIL) peptide 
and an extended SIL peptide as internal standards to track 
digestion variability of an unstable signature peptide during 
quantification of a cancer biomarker, human osteopontin, from 
plasma using capillary microflow LC‑MS/MS. J Chromatogr B 
Analyt Technol Biomed Life Sci 1001: 156‑168, 2015.
103. Meirinho SG, Dias LG, Peres AM and Rodrigues LR: 
Development of an electrochemical RNA-aptasensor to detect 
human osteopontin. Biosens Bioelectron 71: 332‑341, 2015.
104. Chen H, Mei Q, Jia S, Koh K, Wang K and Liu X: High specific 
detection of osteopontin using a three-dimensional copolymer 
layer support based on electrochemical impedance spectroscopy. 
Analyst (Lond) 139: 4476‑4481, 2014.
This work is licensed under a Creative Commons 
Attribution 4.0 International (CC BY 4.0) License.
